Stay up to date with the latest developments in high-risk LBCL and R/R DLBCL with content from key international congresses, video discussions and breaking news stories.
Latest content
ASH 2025
Promising early data for KITE-753 and azer-cel with IL-2 in R/R LBCL
10 December 2025
Prof. Emmanuel Bachy discusses the latest findings for the autologous, rapid manufactured KITE-753 and allogeneic azer-cel in combination with interleukin-2.
Video interview
ASH 2025
10 December 2025
Prof. Emmanuel Bachy discusses the latest findings for the autologous, rapid manufactured KITE-753 and allogeneic azer-cel in combination with interleukin-2.
Image copyright: Emmanuel Bachy
ASH 2025
Rapcabtagene autoleucel my be a viable frontline option in high-risk LBCL
10 December 2025
Dr Jason Westin shares the latest findings on rapcabtagene autoleucel for the treatment of patients with high-risk large B-cell lymphoma autologous in the first-line setting.
Video interview
ASH 2025
10 December 2025
Dr Jason Westin shares the latest findings on rapcabtagene autoleucel for the treatment of patients with high-risk large B-cell lymphoma autologous in the first-line setting.
Image copyright: Jason Westin
ASH 2025
Rapcabtagene autoleucel shows frontline promise for high-risk LBCL
9 December 2025
Early findings show rapcabtagene autoleucel could be a first-line treatment for patients with high-risk LBCL.
News story
ASH 2025
9 December 2025
Early findings show rapcabtagene autoleucel could be a first-line treatment for patients with high-risk LBCL.
Image copyright: © andresr / Getty Images / iStock
ASH 2025
Bispecific, fresh formula CAR-T superior to R-GEMOx in LBCL
9 December 2025
Zamto-cel shows survival benefits over R-GEMOx in patients with R/R LBCL who are ineligible for transplant.
News story
ASH 2025
9 December 2025
Zamto-cel shows survival benefits over R-GEMOx in patients with R/R LBCL who are ineligible for transplant.
Image copyright: © FreemiumStock / Generated with AI / Stock.adobe.com
ASH 2025
Consistent high response with the bispecific prizlo-cel in R/R LBCL
8 December 2025
Prizlo-cel maintains high complete response rates in patients with R/R LBCL in a study looking at the potential effects of correlated biomarkers.
News story
ASH 2025
8 December 2025
Prizlo-cel maintains high complete response rates in patients with R/R LBCL in a study looking at the potential effects of correlated biomarkers.
Image copyright: © [M] David A Litman / stock.adobe.com
ASH 2025
Synergistic CAR-T targeting with rapid manufacturing shows LBCL benefits
8 December 2025
Support for further development of KITE-753 for relapsed/refractory large B-cell lymphoma after findings suggest a rapid and strong response.
News story
ASH 2025
8 December 2025
Support for further development of KITE-753 for relapsed/refractory large B-cell lymphoma after findings suggest a rapid and strong response.
Image copyright: © StockPhotoPro / Stock.adobe.com
Rapid manufacturing: Speeding up access to effective CAR-T cell therapies
30 July 2025
CAR-T-cell therapy has revolutionized the treatment landscape for lymphoma, yet access to this treatment remains constrained by complex and lengthy manufacturing processes.
Clinical commentary
30 July 2025
CAR-T-cell therapy has revolutionized the treatment landscape for lymphoma, yet access to this treatment remains constrained by complex and lengthy manufacturing processes.
Image copyright: © Andrey Popov / stock.adobe.com
EHA 2025
Latest findings from the ATALANTA-1 trial of GLPG5101
19 June 2025
Dr Pim Mutsaers discusses the latest findings from the ATALANTA-1 trial of GLPG5101, which uses a decentralized platform, in patients with R/R NHL.
Video interview
EHA 2025
19 June 2025
Dr Pim Mutsaers discusses the latest findings from the ATALANTA-1 trial of GLPG5101, which uses a decentralized platform, in patients with R/R NHL.
Image copyright: Dr Pim Mutsaers
EHA 2025
CAR-T cell therapy in LBCL and immunotherapy highlights
18 June 2025
Dr Eddie Cliff sets the scene for CAR-T cell therapy in LBCL and gives some of his immunotherapy highlights from the EHA2025 Congress in Milan, Italy.
Video interview
EHA 2025
18 June 2025
Dr Eddie Cliff sets the scene for CAR-T cell therapy in LBCL and gives some of his immunotherapy highlights from the EHA2025 Congress in Milan, Italy.
Image copyright: Dr Eddie Cliff
EHA 2025
Bi-specific CAR-T cell therapy shows promise for R/R LBCL
17 June 2025
Early support for further development of dual CD19 and CD20 targeting in CAR-T cell treatment for patients with relapsed/refractory large-B cell lymphoma.
News story
EHA 2025
17 June 2025
Early support for further development of dual CD19 and CD20 targeting in CAR-T cell treatment for patients with relapsed/refractory large-B cell lymphoma.
Image copyright: © Wimon / stock.adobe.com
EHA 2025
IL-15 polymer conjugate enhances liso-cel response in R/R LBCL
17 June 2025
Promising CAR-T cell expansion and persistence with the addition of NKTR-255 to lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
News story
EHA 2025
17 June 2025
Promising CAR-T cell expansion and persistence with the addition of NKTR-255 to lisocabtagene maraleucel in patients with relapsed/refractory large B-cell lymphoma.
Image copyright: ©David A Litman / stock.adobe.com
EHA 2025
Fast production, low high-grade toxicity with CAR-T cell therapy in R/R NHL
17 June 2025
ATALANTA-1 study shows a manageable safety profile for the CAR T-cell therapy GLPG5101 for patients with relapsed/refractory non-Hodgkin lymphoma
News story
EHA 2025
17 June 2025
ATALANTA-1 study shows a manageable safety profile for the CAR T-cell therapy GLPG5101 for patients with relapsed/refractory non-Hodgkin lymphoma
Image copyright: © shoenberg3 / Stock.adobe.com
EHA 2025
‘High response rates’ with rapcabtagene autoleucel in R/R DLBCL
16 June 2025
The CAR-T cell therapy rapcabtagene autoleucel shows high and durable complete response rates in patients with relapsed/refractory DLBCL.
News story
EHA 2025
16 June 2025
The CAR-T cell therapy rapcabtagene autoleucel shows high and durable complete response rates in patients with relapsed/refractory DLBCL.
Image copyright: © Amornrat Phuchom / Getty Images / iStock
